Brand-name drug
Savaysa price, strengths & recalls
Brand of edoxaban (generic)
Pharmacies pay $464.44 for 30 tablets of Savaysa 30 mg tablet this week, and from $464.45 to $465.35 across its 2 priced strengths and forms. Its official label last changed on July 14, 2025.
Brand- Fair cash price
- $544.61
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Savaysa price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 30 mg tablet Brand | $15.48 | $464.44 / 30 tablets |
| 60 mg tablet Brand | $15.51 | $465.35 / 30 tablets |
Savaysa vs generic edoxaban
There is no generic version of Savaysa on the market yet. Its last listed patent or exclusivity runs to March 28, 2028 - generics often follow, though court cases and settlements can move the date either way.
GenericEdoxaban pricesSupply status: shortages & recalls
What people paid for Savaysa
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use SAVAYSA safely and effectively. See full prescribing information for SAVAYSA. SAVAYSA® (edoxaban) tablets, for oral use Initial U.S. Approval: 2015
WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA
WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
(A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN: SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used (5.1).
(B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS: Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance (2.4, 5.2, 14).
(C) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures (5.4).
A. REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CRCL > 95 ML/MIN
SAVAYSA should not be used in patients with CrCL > 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCL > 95 mL/min had an increased rate of ischemic stroke with SAVAYSA 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used [see Dosage and Administration (2.1), Warnings and Precautions (5.1), and Clinical Studies (14.1)].
B. PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS
Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If SAVAYSA is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance [see Dosage and Administration (2.4), Warnings and Precautions (5.2), and Clinical Studies (14.1)].
C. SPINAL/EPIDURAL HEMATOMA
Epidural or spinal hematomas may occur in patients treated with SAVAYSA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
use of indwelling epidural catheters
concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
a history of traumatic or repeated epidural or spinal punctures
a history of spinal deformity or spinal surgery
optimal timing between the administration of SAVAYSA and neuraxial procedures is not known
[see Warnings and Precautions (5.4)].
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.4)].
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions (5.4)].
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA206316 · Daiichi Sankyo Inc
- First approved
- January 8, 2015 (11 years ago)
- Latest approved change
- October 18, 2023
- Approved label
- PDF, Oct 19, 2023
- Generic makers
- None on the market
- Last patent listed
- March 28, 2028
- Exclusivity ends
- October 18, 2026 (ended)
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Savaysa questions
How much does savaysa cost without insurance?
Pharmacies pay about $464.44 for 30 tablets of savaysa 30 mg tablet ($15.48 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $544.61. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Savaysa?
Yes: edoxaban. Compare edoxaban prices.
Is savaysa in shortage?
No shortage is reported for savaysa right now. We check the national shortage list every day.
Has savaysa been recalled?
No recalls are on record for savaysa.
When did the savaysa label last change?
The official label was last updated on July 14, 2025 (version 28). See what changed.
Talk about savaysa
No comments yet. Questions, tips, what worked for you - start the conversation.